CEL-SCI Corporation
CVM
Rank in Stocks
#25809
CEL-SCI Corporation (CVM) focuses on the research and development of... CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Share Price
$1.35
Last synced: 2026-11-09
Market Cap
$23.75M
Change (1 day)
-6.90%
Change (1 year)
-80.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade CEL-SCI Corporation (CVM)
Category
Healthcare
EPS for CEL-SCI Corporation (CVM)
EPS as of June 2026 TTM: $-2.58
According to CEL-SCI Corporation's latest financial reports, its current EPS (TTM) is $-2.58. At the end of 2025 the company had an EPS of $-6.27, an increase over its 2024 EPS of $-13.50.
EPS history for CEL-SCI Corporation from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.58 | -58.85% |
| 2025 | $-6.27 | -53.56% |
| 2024 | $-13.50 | -38.16% |
| 2023 | $-21.83 | -16.55% |
| 2022 | $-26.16 | -6.20% |
| 2021 | $-27.89 | 12.87% |
| 2020 | $-24.71 | 14.40% |
| 2019 | $-21.60 | -98.72% |
| 2018 | $-1.69K | 2.88% |
| 2017 | $-1.64K | 2,512.44% |
| 2016 | $-62.70 | -76.67% |
| 2015 | $-268.80 | -9.68% |
| 2014 | $-297.60 | 71.33% |
| 2013 | $-173.70 | -62.30% |
| 2012 | $-460.80 | -50.18% |
| 2011 | $-924.90 | -408.30% |
| 2010 | $300.00 | -113.06% |
| 2009 | $-2.30K | 365.59% |
| 2008 | $-493.50 | -33.51% |
| 2007 | $-742.20 | -1.55% |
| 2006 | $-753.90 | 140.48% |
| 2005 | $-313.50 | -33.06% |
| 2004 | $-468.30 | -50.06% |
| 2003 | $-937.80 | -56.91% |
| 2002 | $-2.18K | -41.00% |
| 2001 | $-3.69K | 11.72% |
| 2000 | $-3.30K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -706.98% |
US
|
|
| $-7.07 | 174.03% |
US
|
|
| $-5.29 | 105.04% |
AU
|
|
| $12.88 | -599.23% |
BE
|
|
| $21.56 | -935.66% |
NL
|
Questions about CEL-SCI Corporation's earnings per share (EPS)
What is CEL-SCI Corporation's earnings per share (EPS)?
CEL-SCI Corporation's earnings per share (EPS) over the last twelve months is $-2.58, as of Jun 2026.
What was CEL-SCI Corporation's earnings per share (EPS) in 2025?
In 2025, CEL-SCI Corporation's earnings per share (EPS) was $-6.27, compared with $-13.50 in 2024.
How has CEL-SCI Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, CEL-SCI Corporation's earnings per share (EPS) was highest in 2025 ($-6.27) and lowest in 2021 ($-27.89).
How does CEL-SCI Corporation's earnings per share (EPS) compare with similar companies?
CEL-SCI Corporation's earnings per share (EPS) ($-2.58) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.